Gene Expression and Chemotherapy Response in Colorectal Cancer
Author Information
Author(s): Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R
Primary Institution: Tokyo Medical and Dental University
Hypothesis
The expression levels of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase can predict outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine-based chemotherapy.
Conclusion
Higher levels of orotate phosphoribosyltransferase expression are associated with better response and survival rates in patients undergoing chemotherapy for metastatic colorectal cancer.
Supporting Evidence
- Patients with high OPRT expression had a median survival of 12.5 months compared to 8.5 months for those with low expression.
- Responding tumors had statistically higher OPRT gene expression than nonresponding tumors.
- The study found a significant correlation between OPRT expression and both response and survival in patients treated with UFT and LV.
Takeaway
This study found that measuring certain genes in cancer can help doctors predict how well a treatment will work.
Methodology
The study evaluated gene expressions in tumor samples from patients treated with UFT and LV chemotherapy, analyzing their correlation with treatment response and survival.
Potential Biases
Potential biases may arise from the small sample size and retrospective design.
Limitations
The study is retrospective and involved a limited number of patients.
Participant Demographics
Median age of participants was 62 years, with a range from 38 to 80 years.
Statistical Information
P-Value
0.0008
Confidence Interval
95% confidence interval, 18.0–49.8%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website